Skip to content
OpenCapital
Get started

Pelthos Therapeutics Inc. PTHS Q2 2025 earnings

Reported August 13, 2025 · Before market open

Revenue-Diluted EPS-$5.38Miss by $2.28
EPS estimate-$3.10

Next report

Aug 12, 2026 (in a month)
Revenue estimate$15.2M
EPS estimate-$2.95

Financials

Q2 2025

Income statement

See full
Revenue-—
Gross profit-—
Operating income-$3.2M-83.1%
Net income-$3.4M-94.7%

Balance sheet

See full
Cash & equivalents$59.2K-97.5%
Total equity-$6.5M-3,429%
Total assets$822.9K-68.4%

Cash flow

See full
Operating cash flow-$447.3K+84.9%

Versus estimates

Revenue

Q1 2026$10.9MBeat by $468.3KQ4 2025$9.4MBeat by $298.5KQ3 2025$7.4MMiss by $3.0M

Diluted EPS

Q1 2026-$3.09Beat by $0.36Q4 2025-$2.83Beat by $1.12Q3 2025-$5.30Miss by $4.63
Q2 2025-$5.38Miss by $2.28

Ask the moment Pelthos Therapeutics Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Pelthos Therapeutics Inc. report Q2 2025 earnings?
Pelthos Therapeutics Inc. (PTHS) reported Q2 2025 earnings on August 13, 2025 before market open.
What were Pelthos Therapeutics Inc.'s Q2 2025 revenue and EPS?
Pelthos Therapeutics Inc. reported revenue of - and diluted EPS of $-5.38 for Q2 2025.
Did Pelthos Therapeutics Inc. beat estimates in Q2 2025?
EPS missed the consensus estimate of $-3.10 by $2.28.
Where can I find Pelthos Therapeutics Inc.'s Q2 2025 SEC filings?
You can read the 10-Q periodic report (0001753926-25-001326) directly on SEC EDGAR. The filing index links above go to sec.gov.